Cancer Mutations and Prognosis in Premenopausal, Early-Stage Breast Cancer

Grant number: CCR14299387 | Funding period: 2014 - 2018

Completed

Abstract

Breast cancer arising in young women, particularly those less than 40yrs at diagnosis, has been long been observed to be associated with a poor prognosis independent of clinic-pathological factors. The reasons for this remain unclear. The advent of next generational sequencing technologies (NGS) has given us the ability for the first time to unravel the cancer genome. As such, it promises to reveal new insights into cancer biology that will change how we treat and manage patients. Thus far there have been no attempts to genomically profile breast cancers arising in young women. This could help us understand the biological mechanisms that contribute to their aggressive disease biology. Furthe..

View full description

Related publications (2)

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials

SJ Luen, LC Brown, CT Van Geelen, P Savas, R Kammler, P Dell'orto, O Biasi, AS Coates, RD Gelber, B Thürlimann, M Colleoni, GF Fleming, PA Francis, MM Regan, G Viale, S Loi

2025-01-01

PURPOSE To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER..

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

SJ Luen, G Viale, S Nik-Zainal, P Savas, R Kammler, P Dell'Orto, O Biasi, A Degasperi, LC Brown, I Láng, G MacGrogan, C Tondini, M Bellet, F Villa, A Bernardo, E Ciruelos, P Karlsson, P Neven, M Climent, B Müller

2023-04-01

Background: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-nega..

University of Melbourne Researchers

Sherene Loi